- Silence Therapeutics ( NASDAQ: SLN ) has priced an underwritten offering of 5.95M American Depositary Shares, each representing three ordinary shares, at a price of $9.50/ADS, for aggregate gross proceeds of ~$56.5M.
- All of the ADSs are being offered by Silence.
- Offering is expected to close on or about August 16, 2022.
- Silence intends to use the net proceeds of the offering, together with its existing cash and cash equivalents to fund the advancement of its clinical trials, including its Phase 2 trial of SLN360 in ASCVD and its Phase 1/2 trial of SLN124 in polycythemia vera, as well as expansion of pipeline programs, working capital and general corporate purposes.
For further details see:
Silence Therapeutics prices 5.95M ADSs at $9.50/share